Valinor Pharma

News

Grünenthal's chief executive Gabriel Baertschi

Grünenthal buys Valinor and constipation drug for $250m

German pain medicines specialist Grünenthal has dipped another toe in the M&A waters with a $250 million agreement to buy US drugmaker Valinor Pharma.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks